Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate: A case study of five patients with treatment-resistant inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 6, Issue 4, 2000, Pages 286-289

  Egan, Laurence J ^a   Tremaine, William J ^a   Mays, Dennis C ^a   Lipsky, James J ^a   Sandborn, William J ^a,b  

^a Div Gastroenterol Hepatol Int M   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Crohn's disease; Cyclosporine; Methotrexate; Ulcerative colitis

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ARTICLE; CROHN DISEASE; DRUG ADMINISTRATION; DRUG COMBINATION; HUMAN; RECURRENT DISEASE; TREATMENT OUTCOME; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CROHN DISEASE; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; RECURRENCE; TREATMENT OUTCOME;

EID: 0034326725     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1002/ibd.3780060406     Document Type: Article

References (5)

1. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
2. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologiec remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6.
3. Lemann M, Chamiot-Prieur C, Mesnard B, et al. Methotrexate for the treatment of refractory Crohn's disease. Aliment Pharmacol Ther 1996:10:309-14.
4. Egan LJ, Sandborn WJ, Tremaine WJ, et al. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 1999;13:1597-1604.
5. Vandeputte L, D'Haens G, Baert F, et al. Methotrexate in refractory Crohn's disease. Inflammatory Bowel Diseases 1999;5:11-15.